

Supplementary Material

Identifying Suitable Targets for Alzheimer's Disease and Other Eight Common Neurological Disorders Using the Human Plasma Proteome: A Mendelian Randomization Study

Supplementary Table 1. Reverse causal relationships of plasma proteins with neurological diseases performed by MR.

Exposure	nSNPs	Method	β (se)	<i>p</i>	Q <i>pval</i>	Intercept <i>pval</i>	Global <i>pval</i>
Myeloid cell surface antigen CD33 versus AD	18	IVW	-0.023 (0.034)	0.499	0.843	0.580	0.707
		MR Egger	-0.040 (0.046)	0.392			
		MR-PRESSO	-0.015 (0.028)	0.585			
		Weighted median	-0.066 (0.047)	0.158			
		Weighted mode	-0.079 (0.050)	0.136			
Cyclin-dependent kinase 8 versus ischemic stroke	9	IVW	0.044 (0.129)	0.736	0.635	0.858	0.649
		MR Egger	-0.128 (0.934)	0.895			
		MR-PRESSO	0.044 (0.386)	0.710			
		Weighted median	0.175 (0.171)	0.307			
		Weighted mode	0.237 (0.233)	0.339			
Neuralized E3 ubiquitin-protein ligase 1 versus migraine	23	IVW	-0.071 (0.057)	0.207	1	0.255	1
		MR Egger	0.794 (0.743)	0.297			
		MR-PRESSO	-0.073 (0.020)	0.001			
		Weighted median	-0.075 (0.069)	0.281			
		Weighted mode	-0.078 (0.127)	0.546			
Prolactin versus epilepsy	3	IVW	0.361 (0.407)	0.375	0.177	0.870	0.312
		MR Egger	0.790 (2.145)	0.775			
		MR-PRESSO	0.066 (0.016)	0.001			
		Weighted median	0.109 (0.397)	0.784			
		Weighted mode	-0.181 (0.600)	0.791			
Fc receptor-like protein 4 versus multiple sclerosis	64	IVW	-0.019 (0.040)	0.623	3.61E-26	0.344	<0.001
		MR Egger	0.024 (0.061)	0.688			
		MR-PRESSO	0.004 (0.018)	0.834			
		Outlier-corrected Weighted median	0.008 (0.031)	0.796			
		Weighted mode	0.016 (0.030)	0.610			

AD, Alzheimer's disease; IVW, inverse-variance weighted; MR-PRESSO, Pleiotropy Residual Sum and Outlier; nSNPs, number of single nucleotide polymorphisms; Q_pval, *p*-value of the Cochran Q statistic; SE, Standard Error.

Supplementary Table 2. Power calculation for two-sample MR analysis of plasma proteins on neurological diseases.

Outcome	Sample size	Proportion of cases	OR	R²	Power
Myeloid cell surface antigen CD33 versus AD	63,926	0.34	1.079	0.534	100%
Cyclin-dependent kinase 8 versus ischemic stroke	440,328	0.08	0.927	0.247	100%
Neutralized E3 ubiquitin-protein ligase 1 versus migraine	873,341	0.12	0.914	0.180	100%
Prolactin versus epilepsy	44,889	0.34	1.068	0.227	89%
Fc receptor-like protein 4 versus multiple sclerosis	115,803	0.41	0.929	0.530	100%

AD, Alzheimer's disease; MR, Mendelian randomization; OR, odds ratio; Type-I error rate (α) was set as 0.05.

Supplementary Table 3. Characteristics of selected SNPs for Myeloid cell surface antigen CD33.

SNP	Chr	Pos.	Effect allele	Other allele	EAF	Beta	SE	<i>p</i>	R ²	F statistic
rs181273405	1	113847592	G	T	0.012	-0.601	0.120	5.37E-07	0.0084	27.917
rs1918695	2	84902208	G	C	0.724	-0.126	0.028	7.08E-06	0.0063	21.019
rs344888	2	140083467	T	C	0.340	0.129	0.026	6.31E-07	0.0075	24.848
rs17486095	4	21609494	G	C	0.059	0.246	0.054	4.47E-06	0.0067	22.205
rs78044881	7	130915645	T	C	0.008	0.683	0.149	4.57E-06	0.0073	24.140
rs9298071	8	63928350	C	A	0.094	-0.191	0.043	9.55E-06	0.0062	20.572
rs138967676	8	88826102	A	G	0.011	0.612	0.126	1.23E-06	0.0082	27.217
rs113227419	8	383102	G	C	0.067	-0.252	0.054	3.39E-06	0.0080	26.557
rs72803897	10	57108985	A	G	0.088	0.227	0.045	3.63E-07	0.0082	27.321
rs147372994	10	96654088	G	T	0.061	0.226	0.051	9.33E-06	0.0059	19.609
rs11594486	10	17729832	C	A	0.065	-0.245	0.050	1.02E-06	0.0073	24.244
rs78361338	12	114306019	G	A	0.019	-0.436	0.092	2.24E-06	0.0070	23.387
rs11054265	12	11504539	G	A	0.108	-0.177	0.040	9.55E-06	0.0060	20.066
rs1107478	16	9795190	A	G	0.540	0.133	0.026	1.91E-07	0.0088	29.250
rs75685588	17	50963397	A	T	0.034	-0.329	0.073	7.24E-06	0.0070	23.305
rs62114140	19	51575009	T	C	0.100	-0.249	0.042	4.68E-09	0.0111	37.129
rs62114169	19	51873306	T	C	0.141	0.200	0.039	2.63E-07	0.0097	32.169
rs3865444	19	51727962	A	C	0.329	-0.942	0.021	1.00E-200	0.3916	2123.365
rs77314901	20	22900228	G	A	0.023	-0.380	0.085	7.76E-06	0.0064	21.276
rs7510521	21	22466510	C	T	0.236	0.134	0.030	5.62E-06	0.0065	21.419

Chr, chromosome; EAF, Effect allele frequency; Pos, position; SE, standard error; SNP, single-nucleotide polymorphism. The threshold was set at $p < 1 \times 10^{-5}$.

Supplementary Table 4. Characteristics of selected SNPs for cyclin-dependent kinase 8.

SNP	Chr	Pos.	Effect allele	Other allele	EAF	Beta	SE	<i>p</i>	R ²	F statistic
rs2937268	1	66553607	T	C	0.053	0.268	0.060	7.41E-06	0.0072	23.996
rs115838075	1	147041838	T	A	0.016	0.466	0.100	3.16E-06	0.0069	23.031
rs114627775	1	103308746	G	A	0.047	0.265	0.058	4.37E-06	0.0063	20.910
rs1689804	1	182121598	A	G	0.491	-0.111	0.025	6.31E-06	0.0062	20.443
rs147849632	1	245059378	G	C	0.021	-0.452	0.101	8.32E-06	0.0085	28.449
rs34147598	2	162822349	T	C	0.032	-0.377	0.076	6.92E-07	0.0087	29.011
rs138237447	3	70440238	T	A	0.015	0.505	0.114	9.77E-06	0.0075	24.874
rs7650572	3	171501558	A	G	0.823	-0.152	0.032	2.40E-06	0.0067	22.192
rs28550727	4	180520424	T	C	0.010	-0.591	0.128	4.07E-06	0.0067	22.378
rs12647106	4	4337988	A	G	0.290	-0.129	0.028	2.75E-06	0.0069	22.848
rs575968615	4	170490927	G	A	0.017	-0.474	0.106	7.41E-06	0.0076	25.117
rs74480769	5	40972211	G	A	0.032	-0.510	0.073	3.39E-12	0.0159	53.425
rs6864050	5	76672960	T	C	0.295	0.124	0.028	6.92E-06	0.0064	21.357
rs1157603	7	8517556	A	G	0.985	0.481	0.108	8.91E-06	0.0069	23.030
rs11775501	8	101465070	C	T	0.341	-0.125	0.027	2.82E-06	0.0070	23.156
rs79920736	8	129408584	C	T	0.078	-0.213	0.046	3.98E-06	0.0065	21.625
rs55747605	9	16677509	A	T	0.088	-0.196	0.044	8.71E-06	0.0062	20.437
rs10973731	9	38293885	C	A	0.156	0.169	0.035	1.32E-06	0.0075	25.013
rs113266389	10	6565474	C	T	0.025	0.373	0.081	4.57E-06	0.0069	22.815
rs35516176	10	81722059	T	A	0.060	0.270	0.060	7.41E-06	0.0082	27.383
rs11839354	13	40977804	A	C	0.251	-0.124	0.028	9.12E-06	0.0058	19.270
rs8025499	15	89189984	C	T	0.473	0.113	0.025	6.17E-06	0.0064	21.251
rs117454577	16	2281967	T	C	0.026	-0.382	0.086	9.77E-06	0.0073	24.125
rs117506641	16	56693581	C	G	0.027	-0.388	0.081	1.74E-06	0.0078	25.795
rs9989454	17	21826038	C	T	0.279	-0.124	0.028	7.94E-06	0.0062	20.459
rs8079914	17	7937533	A	G	0.705	-0.122	0.027	8.32E-06	0.0062	20.638
rs78309177	17	52912221	A	G	0.034	-0.321	0.071	5.62E-06	0.0067	22.263
rs4795433	17	26716821	T	C	0.510	0.119	0.025	1.15E-06	0.0071	23.516
rs72967818	18	72033508	A	G	0.139	0.171	0.036	2.14E-06	0.0070	23.312
rs62143206	19	54326212	T	G	0.213	0.262	0.030	1.26E-18	0.0230	77.677
rs73090279	20	8407019	A	G	0.022	0.389	0.087	7.41E-06	0.0066	21.840
rs2829624	21	26569831	T	C	0.256	0.133	0.029	4.90E-06	0.0067	22.336

Chr, chromosome; EAF, Effect allele frequency; Pos, position; SE, standard error; SNP, single nucleotide polymorphism. The threshold was set at $p < 1 \times 10^{-5}$.

Supplementary Table 5. Characteristics of selected SNPs for neuralized E3 ubiquitin-protein ligase 1.

SNP	Chr	Pos.	Effect allele	Other allele	EAF	Beta	SE	<i>p</i>	R ²	F statistic
rs548834381	1	227684581	T	C	0.434	0.121	0.027	9.12E-06	0.0072	23.860
rs61813832	1	156882950	T	C	0.039	0.295	0.066	7.24E-06	0.0065	21.459
rs7580559	2	45449950	C	T	0.534	0.112	0.025	9.77E-06	0.0063	20.840
rs13173656	5	163505869	T	C	0.098	0.186	0.042	7.41E-06	0.0061	20.213
rs183040236	5	126178997	T	C	0.041	-0.280	0.063	8.91E-06	0.0062	20.643
rs6451674	5	43110754	T	C	0.676	0.121	0.027	5.13E-06	0.0064	21.393
rs9276427	6	32711857	C	T	0.493	0.116	0.025	2.29E-06	0.0068	22.497
rs12202773	6	100824250	A	G	0.098	0.189	0.041	4.79E-06	0.0063	21.023
rs6936531	6	2729530	A	G	0.917	0.207	0.045	3.89E-06	0.0065	21.583
rs17683330	7	16736345	G	A	0.407	0.125	0.027	3.55E-06	0.0075	24.913
rs117915747	7	62001515	C	T	0.022	-0.433	0.096	6.61E-06	0.0082	27.376
rs2299255	7	94938786	C	T	0.130	0.272	0.037	2.29E-13	0.0167	55.878
rs115722675	7	45591193	A	G	0.031	0.328	0.072	5.01E-06	0.0065	21.421
rs7383801	7	142340054	T	G	0.031	-0.321	0.072	7.41E-06	0.0062	20.595
rs6993770	8	106581528	T	A	0.282	0.129	0.027	2.69E-06	0.0067	22.290
rs2543061	8	39831647	G	T	0.772	0.138	0.030	3.63E-06	0.0067	22.294
rs77563269	9	92253311	G	C	0.018	-0.435	0.095	4.90E-06	0.0068	22.447
rs116968700	9	79915537	G	A	0.028	-0.343	0.078	9.55E-06	0.0064	21.277
rs2096372	10	129487469	A	T	0.982	0.429	0.095	6.61E-06	0.0064	21.362
rs34226858	11	26176125	G	T	0.391	0.130	0.026	4.79E-07	0.0081	26.899
rs9567814	13	47810394	T	C	0.109	-0.206	0.042	7.76E-07	0.0082	27.240
rs187150569	16	10189376	C	T	0.008	0.640	0.137	2.95E-06	0.0068	22.665
rs148533624	16	2072874	A	C	0.021	0.425	0.087	1.12E-06	0.0074	24.604
rs6070532	20	57171698	A	C	0.118	-0.174	0.038	4.07E-06	0.0063	20.916
rs112408513	20	45775895	T	G	0.011	-0.565	0.126	7.59E-06	0.0072	24.001

Chr, chromosome; EAF, Effect allele frequency; Pos, position; SE, standard error; SNP, single nucleotide polymorphism. The threshold was set at $p < 1 \times 10^{-5}$.

Supplementary Table 6. Characteristics of selected SNPs for prolactin.

SNP	Chr	Pos.	Effect allele	Other allele	EAF	Beta	SE	<i>p</i>	R ²	F statistic
rs9699592	1	6788985	G	A	0.578	0.112	0.025	9.55E-06	0.0061	20.278
rs12145632	1	247393142	C	T	0.162	-0.155	0.034	5.13E-06	0.0065	21.615
rs6546916	2	74872278	C	A	0.928	0.238	0.051	3.47E-06	0.0075	25.060
rs17885909	2	155331020	A	G	0.156	-0.151	0.034	9.33E-06	0.0060	19.909
rs2302153	2	234847823	C	A	0.203	0.140	0.031	4.90E-06	0.0063	21.081
rs13402525	2	28314858	T	G	0.640	-0.119	0.026	3.72E-06	0.0065	21.535
rs7627092	3	116478181	C	G	0.309	0.120	0.026	5.25E-06	0.0061	20.300
rs11717594	3	118201375	A	G	0.027	-0.347	0.077	7.08E-06	0.0063	20.952
rs10051894	5	149159985	A	G	0.456	0.119	0.026	2.88E-06	0.0071	23.456
rs113682140	5	32752151	C	T	0.236	0.140	0.029	1.91E-06	0.0070	23.421
rs6899064	5	60940718	A	G	0.179	-0.155	0.032	1.70E-06	0.0071	23.520
rs9467170	6	24452754	A	G	0.336	0.119	0.026	5.89E-06	0.0064	21.128
rs17062048	6	133294400	C	T	0.031	0.335	0.073	4.47E-06	0.0068	22.497
rs11155993	6	154942072	T	G	0.205	0.139	0.031	7.24E-06	0.0063	20.757
rs10950441	7	13207343	G	A	0.285	0.120	0.027	9.12E-06	0.0059	19.620
rs79971189	7	42406078	T	C	0.014	-0.509	0.109	3.02E-06	0.0070	23.310
rs142120150	8	21315016	C	G	0.057	-0.264	0.060	9.55E-06	0.0075	24.819
rs72671779	8	102461870	G	A	0.086	0.227	0.049	4.37E-06	0.0081	26.852
rs1157007	9	91535433	T	C	0.573	-0.117	0.026	5.13E-06	0.0067	22.174
rs7091050	10	2188690	C	T	0.463	0.111	0.025	7.59E-06	0.0062	20.488
rs10995455	10	64936361	A	G	0.310	0.124	0.027	5.37E-06	0.0066	21.990
rs11815780	10	6409333	A	G	0.045	-0.302	0.064	2.57E-06	0.0078	25.884
rs12779423	10	133351511	A	G	0.106	0.178	0.040	9.55E-06	0.0060	19.868
rs11025062	11	19237979	T	C	0.514	-0.117	0.025	4.47E-06	0.0068	22.602
rs17124538	11	120783369	G	A	0.050	-0.275	0.059	2.82E-06	0.0072	24.016
rs61942975	12	88074484	T	C	0.065	0.251	0.054	3.31E-06	0.0077	25.510
rs142333252	14	42070338	G	A	0.045	-0.321	0.065	6.61E-07	0.0088	29.413
rs1875938	16	10612442	G	C	0.185	0.166	0.033	3.47E-07	0.0083	27.695
rs138645734	17	10655160	C	A	0.021	-0.432	0.095	5.89E-06	0.0079	26.122
rs117268622	19	48295037	T	C	0.029	-0.363	0.081	6.61E-06	0.0073	24.411
rs7249614	19	43637890	G	A	0.578	-0.120	0.027	6.03E-06	0.0070	23.261
rs2867491	20	41286644	T	A	0.299	0.121	0.027	8.13E-06	0.0061	20.332
rs3729555	20	61594493	A	G	0.328	-0.122	0.027	5.25E-06	0.0066	21.754

Chr, chromosome; EAF, Effect allele frequency; Pos, position; SE, standard error; SNP, single nucleotide polymorphism. The threshold was set at $p < 1 \times 10^{-5}$.

Supplementary Table 7. Characteristics of selected SNPs for Fc receptor-like protein 4.

SNP	Chr	Pos.	Effect allele	Other allele	EAF	Beta	SE	<i>p</i>	R ²	F statistic
rs3850533	1	20061456	C	T	0.247	0.137	0.029	1.95E-06	0.0070	23.203
rs76661224	1	210590022	A	G	0.072	0.215	0.048	7.41E-06	0.0062	20.584
rs11582663	1	157559122	T	C	0.144	-1.133	0.030	1.00E-200	0.3169	1530.602
rs1609331	2	184556456	A	G	0.536	0.111	0.025	8.32E-06	0.0061	20.157
rs6436653	2	227972708	G	A	0.613	-0.113	0.026	9.33E-06	0.0061	20.211
rs73104894	2	239544749	A	G	0.019	-0.461	0.092	4.79E-07	0.0080	26.544
rs76470538	3	102579094	C	T	0.027	-0.349	0.077	5.89E-06	0.0065	21.458
rs76866641	3	35950517	A	G	0.022	-0.399	0.089	7.59E-06	0.0069	22.927
rs17676863	4	54610788	T	A	0.028	0.369	0.081	5.01E-06	0.0075	25.030
rs13189930	5	14727882	A	C	0.219	-0.136	0.031	9.33E-06	0.0063	20.849
rs2973719	5	177801274	C	T	0.265	0.123	0.028	9.55E-06	0.0059	19.600
rs150083591	6	141850357	T	C	0.024	0.437	0.090	1.32E-06	0.0090	29.966
rs762808	6	32797466	A	G	0.052	0.250	0.056	8.51E-06	0.0061	20.354
rs76383287	6	43177353	A	G	0.103	-0.179	0.040	9.77E-06	0.0059	19.579
rs116995988	6	162877862	C	T	0.025	0.391	0.080	1.10E-06	0.0074	24.726
rs116921833	7	153895185	T	C	0.011	-0.605	0.128	2.09E-06	0.0077	25.725
rs9648088	7	46659313	T	C	0.220	-0.145	0.031	3.24E-06	0.0072	23.910
rs13257111	8	26582563	A	G	0.591	-0.120	0.026	3.89E-06	0.0069	22.941
rs2974279	8	88075043	C	T	0.640	-0.121	0.026	4.47E-06	0.0067	22.328
rs700089	9	125874636	G	A	0.950	-0.255	0.058	9.55E-06	0.0062	20.578
rs112726374	9	36985873	T	C	0.037	-0.321	0.065	8.91E-07	0.0073	24.357
rs10968633	9	28517171	T	C	0.192	-0.160	0.036	9.55E-06	0.0079	26.369
rs568952649	11	94912324	C	T	0.014	0.538	0.118	5.25E-06	0.0081	27.087
rs10744541	12	1607334	A	G	0.652	0.118	0.026	5.89E-06	0.0063	21.001
rs143328393	13	83919602	T	G	0.026	-0.370	0.080	3.31E-06	0.0068	22.704
rs41307104	14	55835961	C	G	0.017	-0.535	0.102	1.51E-07	0.0093	31.080
rs3809562	15	71148408	G	A	0.579	0.113	0.025	6.03E-06	0.0062	20.744
rs67181813	16	84413537	C	G	0.106	-0.197	0.040	9.55E-07	0.0074	24.515
rs554926389	17	9953082	C	T	0.017	-0.499	0.103	1.29E-06	0.0085	28.124
rs112638217	18	46632188	C	T	0.012	-0.530	0.115	4.37E-06	0.0068	22.745
rs17801029	19	45050756	C	T	0.026	-0.360	0.078	4.37E-06	0.0066	21.929

Chr, chromosome; EAF, Effect allele frequency; Pos, position; SE, standard error; SNP, single nucleotide polymorphism. The threshold was set at $p < 1 \times 10^{-5}$.

Supplementary Table 8. Characteristics of selected SNPs for AD.

SNP	Trait	Chr	Pos.	Effect allele	Other allele	EAF	Beta	SE	<i>p</i>	R ²	F statistic
rs679515	AD	1	207750568	C	T	0.172	-0.151	0.018	1.55E-16	0.0065	415.785
rs6733839	AD	2	127892810	T	C	0.382	0.169	0.015	4.02E-28	0.0135	876.955
rs114812713	AD	6	41034000	C	G	0.019	0.298	0.043	4.47E-12	0.0033	211.220
rs34665982	AD	6	32560306	C	T	0.301	-0.097	0.017	5.8E-09	0.0039	252.620
rs9381563	AD	6	47432637	T	C	0.644	-0.082	0.015	2.93E-08	0.0031	198.105
rs11767557	AD	7	143109139	C	T	0.803	-0.103	0.018	1.56E-08	0.0033	214.198
rs867230	AD	8	27468503	A	C	0.607	0.133	0.016	3.49E-17	0.0085	546.801
rs73223431	AD	8	27219987	T	C	0.367	0.094	0.015	8.34E-10	0.0041	261.118
rs11257242	AD	10	11721119	G	C	0.367	0.084	0.015	4.64E-08	0.0033	210.831
rs1582763	AD	11	60021948	A	G	0.351	-0.123	0.015	1.19E-16	0.0069	445.182
rs3851179	AD	11	85868640	C	T	0.361	0.120	0.015	5.81E-16	0.0066	425.934
rs3740688	AD	11	47380340	T	G	0.553	0.094	0.014	9.7E-11	0.0043	277.456
rs12590654	AD	14	92938855	A	G	0.337	-0.091	0.016	8.73E-09	0.0037	235.164
rs72654445	AD	19	45417200	A	G	0.010	-0.543	0.081	2.27E-11	0.0061	389.606
rs7412	AD	19	45412079	T	C	0.072	-0.467	0.031	6.4E-53	0.0292	1923.980
rs1081105	AD	19	45412955	C	A	0.974	0.942	0.044	1.5E-103	0.0451	3019.937
rs12151021	AD	19	1050874	G	A	0.319	-0.107	0.017	2.56E-10	0.0050	320.277
rs111278137	AD	19	45215081	A	G	0.021	-0.474	0.071	3.2E-11	0.0093	597.580
rs147711004	AD	19	45337918	A	G	0.028	1.135	0.037	1E-200	0.0702	4824.058
rs139136389	AD	19	45427136	T	C	0.020	-0.494	0.085	6.43E-09	0.0094	607.758
rs150685845	AD	19	45675180	G	A	0.988	0.556	0.065	6.62E-18	0.0076	491.785

AD, Alzheimer's disease; Chr, chromosome; EAF, Effect allele frequency; Pos, position; SE, standard error; SNP, single nucleotide polymorphism. The threshold was set at $p < 5 \times 10^{-8}$.

Supplementary Table 9. Characteristics of selected SNPs for multiple sclerosis.

SNP	Chr	Pos.	Effect allele	Other allele	EAF	Beta	SE	<i>p</i>	R ²	F statistic
rs10063294	5	35877505	A	G	0.529	-0.099	0.016	1.13E-09	0.0049	568.834
rs1014486	3	159691112	C	T	0.419	0.105	0.016	1.36E-10	0.0054	625.971
rs1026916	17	40529835	G	A	0.652	-0.130	0.017	1.02E-13	0.0076	890.047
rs1077667	19	6668972	T	C	0.207	-0.152	0.021	8.37E-13	0.0076	883.265
rs10801908	1	117090493	T	C	0.120	-0.215	0.026	3.54E-16	0.0097	1139.566
rs1112718	10	94479107	G	A	0.407	-0.106	0.017	2.46E-10	0.0054	626.895
rs11256593	10	6117322	T	C	0.530	0.186	0.017	6.78E-27	0.0173	2038.135
rs114872782	6	32241452	T	C	0.014	-2.450	0.255	7.72E-22	0.1692	23577.340
rs11666263	19	10590684	G	A	0.364	-0.103	0.018	1.2E-08	0.0049	569.458
rs11749040	5	40396425	A	G	0.128	0.197	0.023	3.54E-17	0.0087	1012.071
rs1177228	2	61242410	G	A	0.722	0.107	0.019	8.57E-09	0.0046	538.596
rs11809700	1	93152635	T	C	0.268	0.144	0.018	3.51E-15	0.0082	956.310
rs12147246	14	103265844	G	A	0.654	-0.099	0.017	4.29E-09	0.0045	519.580
rs12365699	11	118743286	A	G	0.159	-0.144	0.023	3.15E-10	0.0055	645.001
rs12434551	14	69253364	T	A	0.456	-0.104	0.016	1.83E-10	0.0054	623.553
rs12478539	2	43355324	C	G	0.279	-0.123	0.019	4.37E-11	0.0061	712.036
rs1250551	10	81059335	T	G	0.366	0.116	0.017	2.66E-11	0.0062	724.179
rs12612620	2	112488876	A	G	0.233	0.212	0.036	4.26E-09	0.0160	1885.159
rs12925972	16	79111297	C	T	0.547	0.095	0.017	3.07E-08	0.0044	515.658
rs13327021	3	27783015	T	C	0.350	0.115	0.017	1.73E-11	0.0060	703.581
rs140522	22	50971266	C	T	0.671	-0.111	0.018	2.85E-10	0.0054	628.367
rs1465697	19	49837246	T	C	0.255	0.124	0.019	3.48E-11	0.0059	683.274
rs17124032	14	88546009	A	G	0.071	-0.217	0.032	7.08E-12	0.0062	724.597
rs1738074	6	159465977	C	T	0.582	0.114	0.017	9.91E-12	0.0063	733.588
rs1860545	12	6446777	A	G	0.392	0.117	0.017	7.79E-12	0.0065	754.758
rs2150879	17	57859210	A	G	0.559	-0.104	0.016	3.29E-10	0.0053	615.515
rs2248461	20	52792202	A	G	0.370	-0.108	0.017	5.33E-10	0.0055	634.523
rs2317231	1	157686337	T	G	0.450	-0.101	0.017	1.9E-09	0.0050	582.686
rs2546890	5	158759900	G	A	0.475	-0.117	0.016	1.04E-12	0.0068	795.841
rs2681424	3	121769522	C	T	0.504	-0.121	0.017	2.71E-13	0.0073	856.112
rs2857700	6	31572481	C	T	0.867	-0.767	0.024	1E-200	0.1356	18163.960
rs28703878	8	79417222	G	A	0.277	0.134	0.021	4.51E-10	0.0072	835.067
rs34695601	14	76014298	C	T	0.264	-0.109	0.020	3.16E-08	0.0047	541.420
rs354033	7	149289464	A	G	0.250	-0.108	0.019	1.21E-08	0.0044	508.237
rs35486093	1	85729820	G	A	0.093	0.179	0.028	1.6E-10	0.0054	633.773
rs35540610	2	231121829	C	T	0.246	0.135	0.019	2.88E-12	0.0068	789.494

rs35703946	16	86021505	A	G	0.163	-0.173	0.029	1.94E-09	0.0081	948.333
rs3809627	16	30103160	A	C	0.400	-0.097	0.018	3.25E-08	0.0045	524.901
rs415759	16	1066917	C	T	0.186	0.119	0.022	4.76E-08	0.0043	497.112
rs4325907	3	101749022	T	C	0.643	-0.099	0.017	3.68E-09	0.0045	525.974
rs438613	3	28072086	C	T	0.470	0.138	0.017	9.43E-17	0.0095	1109.665
rs478093	1	120255126	G	A	0.684	0.105	0.018	4.3E-09	0.0048	556.488
rs4808760	19	18301979	G	C	0.293	-0.135	0.019	4.84E-13	0.0075	874.419
rs4896153	6	135833463	A	T	0.631	-0.138	0.019	1.65E-13	0.0089	1041.312
rs4939490	11	60793651	G	C	0.397	0.137	0.017	4.25E-15	0.0089	1044.446
rs4947255	6	32207483	T	C	0.035	-0.552	0.056	2.54E-23	0.0203	2404.728
rs55970742	7	2441337	T	C	0.674	-0.100	0.018	2.05E-08	0.0044	515.255
rs56232455	11	321235	A	G	0.487	0.158	0.028	1.78E-08	0.0125	1470.438
rs58546351	6	32483611	G	A	0.008	-1.894	0.053	1E-200	0.0559	6857.161
rs59655222	1	200875897	C	T	0.298	-0.123	0.019	3.76E-11	0.0064	740.138
rs6032662	20	44734310	T	C	0.756	-0.134	0.018	2.85E-13	0.0066	770.427
rs62420820	6	137438057	A	G	0.238	0.137	0.019	2.5E-13	0.0068	796.445
rs6496663	15	90887584	C	A	0.295	0.101	0.018	2.78E-08	0.0042	489.348
rs6670198	1	2520527	C	T	0.346	-0.145	0.018	2.03E-16	0.0095	1113.184
rs6763437	3	119145390	A	G	0.041	-0.779	0.132	3.72E-09	0.0477	5800.974
rs6990534	8	128814091	G	A	0.710	0.107	0.018	3.6E-09	0.0047	550.312
rs701006	12	58106836	G	A	0.600	0.114	0.017	1.35E-11	0.0062	725.038
rs7190580	16	11403470	G	A	0.711	-0.098	0.018	4.64E-08	0.0040	459.280
rs7200146	16	11213449	T	G	0.657	-0.171	0.017	7E-24	0.0131	1541.765
rs7207542	17	45697549	G	C	0.497	0.109	0.017	4.67E-11	0.0059	689.002
rs72928038	6	90976768	A	G	0.174	0.161	0.025	9.01E-11	0.0074	862.915
rs743771	6	32976909	A	C	0.466	-0.099	0.016	8.55E-10	0.0049	572.214
rs74449127	1	101290432	G	A	0.292	-0.197	0.026	1.36E-14	0.0160	1888.336
rs7592560	2	68647001	A	G	0.549	0.104	0.017	2.87E-10	0.0054	624.710
rs7855251	9	100868189	C	T	0.256	-0.110	0.020	4.23E-08	0.0046	536.698
rs7975763	12	123604053	T	C	0.210	0.121	0.021	7.8E-09	0.0049	566.386
rs9277647	6	33083750	T	C	0.190	-0.214	0.021	5.47E-24	0.0140	1649.409
rs9393975	6	29802217	A	T	0.177	-0.766	0.043	1.49E-70	0.1710	23891.210
rs9591325	13	50811220	C	T	0.068	-0.212	0.034	4.16E-10	0.0057	663.126
rs9610458	22	22205353	T	C	0.522	0.114	0.017	4.57E-12	0.0065	758.871
rs9955954	18	56348044	G	A	0.236	-0.110	0.019	1.54E-08	0.0044	508.117
rs9992763	4	109058718	T	G	0.568	-0.090	0.016	4.51E-08	0.0040	462.626

Chr, chromosome; EAF, Effect allele frequency; MS, multiple sclerosis; Pos, position; SE, standard error; SNP, single nucleotide polymorphism. The threshold was set at $p < 5 \times 10^{-8}$.

Supplementary Table 10. Characteristics of selected SNPs for epilepsy.

SNP	Chr	Pos.	Effect allele	Other allele	EAF	Beta	SE	<i>p</i>	R²	F statistic
rs6432877	2	166998767	G	C	0.255	0.063	0.009	1.7E-13	0.0015	68.739
rs4671319	2	57950346	A	G	0.542	-0.042	0.007	8.07E-09	0.0009	39.123
rs4638568	16	50045839	A	G	0.061	-0.086	0.016	4E-08	0.0008	37.861

Chr, chromosome; EAF, Effect allele frequency; Pos, position; SE, standard error; SNP, single nucleotide polymorphism. The threshold was set at $p < 5 \times 10^{-8}$.

Supplementary Table 11. Characteristics of selected SNPs for ischemic stroke.

SNP	Chr	Pos.	Effect allele	Other allele	EAF	Beta	SE	<i>p</i>	R ²	F statistic
rs2758612	1	156205301	C	T	0.355	-0.065	0.011	3.68E-09	0.0020	861.196
rs34311906	4	113732090	C	T	0.402	0.065	0.011	1.07E-08	0.0020	893.805
rs2634074	4	111677041	A	T	0.788	-0.094	0.012	5.9E-15	0.0030	1307.924
rs2066864	4	155525695	A	G	0.245	0.063	0.012	3.51E-08	0.0015	656.118
rs11242678	6	1337180	T	C	0.255	0.072	0.011	2.7E-10	0.0020	876.276
rs2107595	7	19049388	A	G	0.167	0.088	0.013	2.33E-11	0.0022	956.463
rs473238	11	102700360	C	T	0.867	-0.083	0.015	1.65E-08	0.0016	700.583
rs3184504	12	111884608	C	T	0.528	-0.078	0.010	1.23E-14	0.0030	1335.950
rs4942561	13	47209347	T	G	0.759	0.066	0.012	1.77E-08	0.0016	692.194

Chr, chromosome; EAF, Effect allele frequency; Pos, position; SE, standard error; SNP, single nucleotide polymorphism. The threshold was set at $p < 5 \times 10^{-8}$.

Supplementary Table 12. Characteristics of selected SNPs for migraine.

SNP	Chr	Pos.	Effect allele	Other allele	EAF	Beta	SE	<i>p</i>	R ²	F statistic
rs11172113	12	57527283	C	T	0.415	-0.107	0.005	1.38E-90	0.0055	4859.749
rs4759276	12	57526646	A	G	0.392	-0.104	0.005	7.05E-83	0.0052	4539.210
rs4759275	12	57525756	A	G	0.426	-0.097	0.005	7.31E-74	0.0046	4018.044
rs10218452	1	3075597	G	A	0.229	0.110	0.006	7.26E-71	0.0043	3747.233
rs7518255	1	3086464	A	G	0.224	0.108	0.006	1.35E-70	0.0040	3527.335
rs10797381	1	3072482	A	T	0.229	0.109	0.006	4.13E-70	0.0042	3704.242
rs2075968	1	3081241	T	C	0.225	0.107	0.006	6.49E-70	0.0040	3512.754
rs61759167	1	3091587	T	C	0.224	0.108	0.006	2.82E-69	0.0040	3533.697
rs10467124	12	57519694	C	G	0.429	-0.093	0.005	6.77E-69	0.0042	3707.791
rs2376495	1	3095126	G	C	0.224	0.108	0.006	7.76E-69	0.0041	3552.668
rs11587518	1	3096925	A	T	0.224	0.108	0.006	9.23E-69	0.0041	3551.699
rs28594467	1	3097051	T	C	0.224	0.108	0.006	9.96E-69	0.0041	3552.248
rs56304645	1	3085186	T	C	0.231	0.106	0.006	1.59E-68	0.0040	3468.542
rs1393064	1	3099138	C	G	0.223	0.109	0.006	2.77E-68	0.0041	3595.500
rs11172111	12	57515804	G	T	0.425	-0.093	0.005	3.00E-68	0.0043	3728.150
rs11172110	12	57515769	C	T	0.429	-0.092	0.005	3.86E-68	0.0042	3664.627
rs12298170	12	57515363	G	A	0.430	-0.092	0.005	1.19E-67	0.0041	3611.042
rs10876963	12	57514554	C	T	0.430	-0.092	0.005	1.36E-67	0.0041	3613.244
rs12322902	12	57513866	G	A	0.431	-0.092	0.005	2.80E-67	0.0042	3645.527
rs12309413	12	57513879	G	C	0.432	-0.092	0.005	1.22E-66	0.0041	3620.639
rs10909886	1	3066761	T	A	0.232	0.109	0.006	6.06E-66	0.0042	3698.620
rs61759161	1	3065568	T	C	0.229	0.110	0.006	2.85E-65	0.0043	3734.556
rs4257011	12	57528197	A	G	0.350	-0.092	0.006	5.95E-63	0.0039	3404.314
rs10747776	12	57528679	A	G	0.350	-0.092	0.006	7.82E-63	0.0039	3395.784

Chr, chromosome; EAF, Effect allele frequency; Pos, position; SE, standard error; SNP, single nucleotide polymorphism. The threshold was set at $p < 1 \times 10^{-60}$.

Table S13. Mendelian randomization results of possible plasma proteins on Alzheimer's diseases.

Trait	nSNPs	Method	OR (95%CI)	<i>p</i>	Q pval	Intercept pval	Global pval
Leucine-rich repeat neuronal protein 1	22	IVW	2.217 (1.850, 2.656)	6.24E-18	5.66E-193		
		MR Egger	2.902 (2.413, 3.489)	2.09E-10			
		MR-PRESSO	2.189 (1.835, 2.611)	6.79E-09			
		Weighted median	2.372 (1.888, 2.980)	1.22E-13			
		Weighted mode	2.771 (2.624, 2.925)	2.90E-21			
Vacuolar protein sorting-associated protein 29	22	IVW	0.806 (0.766, 0.849)	4.64E-16	2.83E-06		
		MR Egger	0.755 (0.718, 0.793)	5.65E-10			
		MR-PRESSO	0.824 (0.781, 0.869)	1.40E-07			
		Weighted median	0.765 (0.737, 0.795)	7.86E-44			
		Weighted mode	0.759 (0.731, 0.788)	2.22E-12			
Protein S100-A13	22	IVW	0.500 (0.413, 0.605)	1.33E-12	2.54E-196		
		MR Egger	0.349 (0.305, 0.400)	1.98E-12			
		MR-PRESSO	0.514 (0.427, 0.618)	2.66E-07			
		Weighted median	0.736 (0.627, 0.862)	1.55E-04			
		Weighted mode	0.381 (0.359, 0.405)	3.39E-19			
Cardiotrophin-1	20	IVW	2.556 (1.860, 3.512)	7.23E-09	4.86E-310		
		MR Egger	4.496 (3.235, 6.249)	4.78E-08			
		MR-PRESSO	2.556 (1.860, 3.512)	1.42E-05			
		Weighted median	1.030 (0.932, 1.138)	0.561			
		Weighted mode	0.966 (0.853, 1.095)	0.598			
Proteasome activator complex subunit 1	18	IVW	0.777 (0.696, 0.867)	6.92E-06	4.21E-17		
		MR Egger	0.659 (0.580, 0.748)	8.63E-06			
		MR-PRESSO	0.793 (0.714, 0.882)	3.5E-04			
		Weighted median	0.745 (0.655, 0.847)	6.75E-06			
		Weighted mode	0.645 (0.603, 0.690)	3.91E-10			
MAP kinase-activated protein kinase 5	25	IVW	1.083 (1.042, 1.125)	3.94E-05	5.76E-04		
		MR Egger	1.124 (1.059, 1.194)	8.21E-04			
		MR-PRESSO	1.085 (1.036, 1.137)	1.75E-03			
		Weighted median	1.099 (1.029, 1.173)	4.70E-03			
		Weighted mode	1.178 (1.102, 1.260)	6.65E-05			

AD, Alzheimer's disease; CI, confidence interval; IVW, inverse-variance weighted; MR-PRESSO, Mendelian randomization-Pleiotropy Residual Sum and Outlier, nSNPs, number of single nucleotide polymorphisms; OR, odds ratio; Q_pval, p-value of the Cochran Q statistic.

Supplementary Table 14. STROBE-MR reporting guidelines

Relevant section	Item	Instruction	Location addressed in this article
TITLE and ABSTRACT	TITLE and ABSTRACT	Indicate Mendelian randomization as the study's design in the title and/or the abstract.	Title and abstract
INTRODUCTION	Background	Explain the scientific background and rationale for the reported study. Is causality between exposure and outcome plausible? Justify why MR is a helpful method to address the study question.	Introduction
METHODS	Objectives	State specific objectives clearly, including pre-specified causal hypotheses (if any).	Introduction
	Study design and data sources	Present key elements of study design early in the paper. Consider including a table listing sources of data for all phases of the study. For each data source contributing to the analysis, describe the following: a) Describe the study design and the underlying population from which it was drawn. Describe also the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection, if available. b) Give the eligibility criteria, and the sources and methods of selection of participants. c) Explain how the analyzed sample size was arrived at. d) Describe measurement, quality and selection of genetic variants. e) For each exposure, outcome and other relevant variables, describe methods of assessment and, in the case of diseases, the diagnostic criteria used. f) Provide details of ethics committee approval and participant informed consent, if relevant.	a) Abstract, Introduction, Methods, Figure 1, Table 1 b) Methods c) Methods d) Methods e) Methods f) Methods
	Assumptions	Explicitly state assumptions for the main analysis (e.g., relevance, exclusion, independence, homogeneity) as well assumptions for any additional or sensitivity analysis.	Methods, Figure 1
	Statistical methods: main analysis	Describe statistical methods and statistics used. a) Describe how quantitative variables were handled in the analyses (i.e., scale, units, model). b) Describe the process for identifying genetic variants and weights to be included in the analyses (i.e., independence and model). Consider a flow diagram. c) Describe the MR estimator, e.g., two-stage least squares, Wald ratio, and related statistics. Detail the included covariates and, in case of two-sample MR, whether the same covariate set was used for adjustment in the two samples. d) Explain how missing data were addressed. e) If applicable, say how multiple testing was dealt with	a) Methods b) Methods c) Methods d) Methods e) Methods
	Assessment of assumptions	Describe any methods used to assess the assumptions or justify their validity	Methods
	Sensitivity analyses	Describe any sensitivity analyses or additional analyses performed.	Methods
Software and	a) Name statistical software and package(s), including version and settings used; b)	Methods	

	pre-registration	State whether the study protocol and details were pre-registered (as well as when and where).	
RESULTS	Descriptive data	<p>a) Report the numbers of individuals at each stage of included studies and reasons for exclusion. Consider use of a flow diagram.</p> <p>b) Report summary statistics for phenotypic exposure(s), outcome(s) and other relevant variables (e.g., means, standard deviations, proportions).</p> <p>c) If the data sources include meta-analyses of previous studies, provide the number of studies, their reported ancestry, if available, and assessments of heterogeneity across these studies. Consider using a supplementary table for each data source.</p> <p>d) For two-sample Mendelian randomization:</p> <p>i. Provide information on the similarity of the genetic variant exposure associations between the exposure and outcome samples.</p> <p>ii. Provide information on extent of sample overlap between the exposure and outcome data sources</p>	<p>a) Methods, Figure 1, Table 1</p> <p>b) Supplementary Tables</p> <p>c) N/A</p> <p>d) Methods</p> <p>i. N/A</p> <p>ii. N/A</p>
	Main results	<p>a) Report the associations between genetic variant and exposure, and between genetic variant and outcome, preferably on an interpretable scale (e.g., comparing 25th and 75th percentile of allele count or genetic risk score, if individual-level data available).</p> <p>b) Report causal effect estimate between exposure and outcome, and the measures of uncertainty from the MR analysis. Use an intuitive scale, such as odds ratio, or relative risk, per standard deviation difference.</p> <p>c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time-period.</p> <p>d) Consider any plots to visualize results (e.g., forest plot, scatterplot of associations between genetic variants and outcome versus between genetic variants and exposure)</p>	<p>a) N/A, no individual level data available</p> <p>b) Results, Supplementary Tables</p> <p>c) N/A</p> <p>d) N/A</p>
	Assessment of assumptions	<p>a) Assess the validity of the assumptions.</p> <p>b) Report any additional statistics (e.g., assessments of heterogeneity, such as I^2, Q statistic)</p>	<p>a) Methods, Results, Supplementary Tables</p> <p>b) Results, Table 2</p>
	Sensitivity and additional analyses	<p>a) Use sensitivity analyses to assess the robustness of the main results to violations of the assumptions.</p> <p>b) Report results from other sensitivity analyses (e.g., replication study with different dataset, analyses of subgroups, validation of instrument(s), simulations, etc.).</p> <p>c) Report any assessment of direction of causality (e.g., bidirectional MR).</p> <p>d) When relevant, report and compare with estimates from non-MR analyses.</p> <p>e) Consider any additional plots to visualize results (e.g., leave-one-out analyses).</p>	<p>a) Results, Table 2</p> <p>b) Results</p> <p>c) Results, Figure 1, and Supplementary Table S1</p> <p>d) Introduction, Discussion</p> <p>e) N/A</p>
DISCUSSION	Key results	Summarize key results with reference to study objectives.	Discussion
	Limitations	Discuss limitations of the study, taking into account the validity of the MR assumptions, other sources of potential bias, and imprecision. Discuss both direction and magnitude of any potential bias, and any efforts to address them.	Methods, Discussion
	Interpretation	a) Give a cautious overall interpretation of results considering objectives and	a) Discussion

OTHER INFORMATION		limitations. Compare with results from other relevant studies. b) Discuss underlying biological mechanisms that could be modelled by using the genetic variants to assess the relationship between the exposure and the outcome. c) Discuss whether the results have clinical or policy relevance, and whether interventions could have the same size effect.	b) Discussion c) Abstract, Discussion
	Generalizability	Discuss the generalizability of the study results (a) to other populations (i.e., external validity), (b) across other exposure periods/timings, and (c) across other levels of exposure.	a) Discussion b) Discussion c) N/A
	Funding	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study or studies on which the present article is based.	Study Funding
	Data and data sharing	Present data used to perform all analyses or report where and how the data can be accessed. State whether statistical code is publicly accessible and if so, where.	Methods, Table 1, acknowledgment
	Conflicts of Interest	All authors should declare all potential conflicts of interest.	Disclosure

STROBE-MR, Strengthening the Reporting of Observational Studies in Epidemiology-Mendelian Randomization.